GABA transporter SLC6A11 gene polymorphism associated with tardive dyskinesia

Nordic Journal of Psychiatry

Volumn 68, Issue 2, 2014, Pages 123-128

  Son, Woo Young ^a,b   Lee, Heon Jeong ^a,c   Yoon, Ho Kyoung ^a   Kang, Seung Gul ^d   Park, Young Min ^e   Yang, Hee Jung ^a   Choi, Jung Eun ^a,c   An, Hyonggin ^c   Seo, Han Kyu ^f   Kim, Leen ^a  

^a College of Medicine   (South Korea)

^b Department of Molecular Biology and Genetics   (United States)

^c Korea University College of Medicine   (South Korea)

^d Gachon University   (South Korea)

^e Inje University   (South Korea)

^f BMS   (South Korea)

Author keywords

GABA; Polymorphism; Tardive dyskinesia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA3; 4 AMINOBUTYRIC ACID CARRIER; 4 AMINOBUTYRIC ACID RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; GABA TRANSPORTER 3; NEUROLEPTIC AGENT; SCL6A11 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; EPISTASIS; GENE EXPRESSION; GENE FREQUENCY; GENE INTERACTION; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MULTIFACTOR DIMENSIONALITY REDUCTION; POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURED INTERVIEW; TARDIVE DYSKINESIA;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; FEMALE; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; REPUBLIC OF KOREA; SCHIZOPHRENIA;

EID: 84893068496     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2013.780260     Document Type: Article

References (29)

1. Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: A study in three rat strains. Psychopharmacology (Berl) 1990; 102: 474 - 8.
2. Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry 1981; 138: 1618 - 9.
3. Tarsy D, Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1977; 12: 431 - 50.
4. Casey DE, Gerlach, Magelund G, Christensen TR. gamma- Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry 1980; 37: 1376 - 9.
5. Nagao T, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerobrospinal fl uid monomaine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry 1979; 14: 509 - 23.
6. Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000; 61: 525 - 41.
7. Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: Current concepts and future perspectives. Drugs Today 2003; 39: 19 - 49.
8. Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984; 309: 347 - 9.
9. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy. Am J Psychiatry 1990; 147: 445 - 51.
10. Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008; 18: 317 - 23.
11. Han OS, Hong JP. Structured Clinical Interview for DSM-IV AxisiDisorder - Korean Version. Seoul: Hana Medical Publishing; 2000.
12. Lee HJ, Kang SG, Choi JE, Paik JW, Kim YK, Kim SH, et al. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. Neuropsychobiology 2007; 55: 47 - 51.
13. Lee HJ, Kang SG, Paik JW, Lee MS, Cho BH, Park YM, et al. No evidence for an association between G protein ? 3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia. Hum Psychopharmacol 2007; 22: 501 - 4.
14. Lee HJ, Kang SG, Choi JE, Park YM, Lim SW, Rhee MK, et al. No evidence for association between tyrosine hydroxylase gene Val81Met polymorphism and susceptibility to tardive dyskinesia in schizophrenia. Psychiatry Investig 2009; 6: 108 - 11.
15. Kang SG, Choi JE, An H, Lim SW, Lee HJ, Han C, et al. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1545 - 8.
16. Kang SG, Choi JE, An H, Park YM, Lee HJ, Han C, et al. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1844 - 7.
17. Kang SG, Choi JE, Park YM, Lee HJ, Han C, Kim YK, et al. Val158Met polymorphism in the catechol- O -methyltransferase (COMT) gene is not associated with tardive dyskinesia in schizophrenia. Neuropsychobiology 2008; 57: 22 - 5.
18. Kang SG, Lee HJ, Choi JE, An H, Rhee M, Kim L. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum Psychopharmacol 2009; 24: 55 - 60.
19. Park YM, Kang SG, Choi JE, Kim YK, Kim SH, Park JY, et al. No evidence for an association between dopamine D2 receptor polymorphisms and tardive dyskinesia in Korean schizophrenia patients. Psychiatry Investig 2011; 8: 49 - 54.
20. Kim IS, Yoon HK, Kang SG, Park YM, Kim YK, Kim SH, et al. No association between PAWR gene polymorphisms and tardive dyskinesia in schizophrenia patients. Psychiatry Investig 2012; 9: 191 - 4.
21. Guy W. Abnormal Involuntary Movement Scale (AIMS); ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare; 1976. p. 534 - 537.
22. Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486 - 7.
23. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G * Power 3.1: Tests for correlation and regression analyses. Behav Res Methods 2009; 41: 1149 - 60.
24. Ritchie MD, Hahn LW, Moore JH. Power of multifactor dimensionality reduction for detecting gene - gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003; 24: 150 - 7.
25. Motsinger AA, Ritchie MD. The effect of reduction in crossvalidation intervals on the performance of multifactor dimensionality reduction. Genet Epidemiol 2006; 30: 546 - 55.
26. Chung Y, Lee SY, Elston RC, Park T. Odds ratio based multifactordimensionality reduction method for detecting gene - gene interactions. Bioinformatics 2007; 23: 71 - 6.
27. Delfs JM, Ellison GD, Mercugliano M, Chesselet MF. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Exp Neurol 1995; 133: 175-88.
28. Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman JA, North KE, et al. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 336 - 40.
29. Han GR, Lee YW, Lee HL, Kim SM, Ku TW, Kang IH, et al. A Korean population study of the nine STR loci FGA, VWA, D3S1358, D18S51, D21S11, D8S1179, D7S820, D13S317 and D5S818. Int J Legal Med 2000; 114: 41-4.